Tacrolimus (FK506) reduces ischemia-induced hippocampal damage in rats: a 7- and 30-day study

Abstract

The neuroprotective effect of the immunosuppressant agent FK506 was evaluated in rats after brain ischemia induced for 15 min in the 4-vessel occlusion model. In the first experimental series, single doses of 1.0, 3.0 or 6.0 mg FK506/kg were given intravenously (iv) immediately after ischemia. In the second series, FK506 (1.0 mg/kg) was given iv at the beginning of reperfusion, followed by doses applied intraperitoneally (ip) 6, 24, 48, and 72 h post-ischemia. The same protocol was used in the third series except that all 5 doses were given iv. Damage to the hippocampal field CA1 was assessed 7 or 30 days post-ischemia on three different stereotaxic planes along the septotemporal axis of the hippocampus. Ischemia caused marked neurodegeneration on all planes (P<0.001). FK506 failed to provide neuroprotection to CA1 both when applied iv as a single dose of 1.0, 3.0 or 6.0 mg/kg (experiment 1), and after five iv injections of 1.0 mg/kg (experiment 3). In contrast, the repeated administration of FK506 combining iv plus ip administration reduced CA1 cell death on all stereotaxic planes both 7 and 30 days post-ischemia (experiment 2; P<0.01). Compared to vehicle alone, FK506 reduced rectal temperature in a dose-dependent manner (P<0.05); however, this effect did not alter normothermia (37°C). FK506 reduced ischemic brain damage, an effect sustained over time and apparently dependent on repeated doses and on delivery route. The present data extend previous findings on the rat 4-vessel occlusion model, further supporting the possible use of FK506 in the treatment of ischemic brain damage.

Key words
- Cerebral ischemia
- Hippocampal cell death
- FK506
- Sustained neuroprotection

Introduction

Humans often suffer transient, global cerebral ischemia resulting from cardiocirculatory arrest or cardiopulmonary bypass surgery. In humans (1,2) and in experimental animals (3,4), brief interruptions of cerebral blood flow cause irreversible neuronal damage to vulnerable brain regions such as the hippocampus, striatum and cortex.

In evaluations of neuroprotectors, the use of immunophilin ligands is viewed as a novel and potentially useful strategy. The importance of immunophilins in the development of neuroprotectors emerged from observations that compound FK506 provides neuroprotection against glutamate-induced neurotoxicity in vitro (5), and in the rodent model...
of focal cerebral ischemia employing intra-cerebrally applied endothelin-1 (6). These findings have been extended to models of transient global forebrain ischemia (7-10). FK506 is a fungal-derived macrolide exhibiting a potent immunosuppressant action, and has been recently introduced in clinical practice to prevent allograft rejection. The mechanism by which FK506 prevents ischemic brain damage is not understood, and may depend on de novo protein synthesis (11) rather than on the inhibition of calcineurin (11,12). Since FK506 is already permitted for human use, and considering that it crosses the blood-brain barrier (13), it could be a promising candidate to enter clinical trials as a neuroprotective agent.

However, data obtained from animal models of global cerebral ischemia in vivo are still limited. Three studies employing FK506 have been performed using the gerbil model of global ischemia (7-9) and one study used the rat 2-vessel occlusion + hypotension model (10). The possible influence of drug-induced hypothermia in these studies is controversial. Only a single study has investigated whether the neuroprotective effects of FK506 are sustained for post-ischemic periods longer than the commonly used 4-7-day survival time (7). This is an important aspect of neuroprotection since some treatments may merely delay, rather than prevent ischemia-induced cell loss (14).

There is a need for further investigation of the neuroprotective effects of FK506 in the rat, using the 4-vessel occlusion (4-VO) model (15). In an initial experiment, we attempted to reproduce a previous finding of robust neuroprotection in the gerbil after a single intravenous (iv) dose of FK506 (7). Given the unexpected negative results, subsequently we assessed the effects of FK506 applied in repeated doses, employing a combination of iv and intraperitoneal (ip) administration. The effects of FK506 were assessed at two different post-ischemic survival times, and evaluated in different rostro-caudal portions of the CA1 subfield. In a third experiment, we investigated improvement in FK506 neuroprotection by restricting the administration of repeated doses to the iv route.

Material and Methods

Animals

Adult male Wistar rats weighing 270-300 g were housed in groups of three to four in plastic cages (39 x 33 x 16 cm) at controlled temperature (22 ± 1°C) on a 12-h light/dark cycle (lights on at 7:00 h) with constant air exchange. Food and water were offered ad libitum. These housing conditions were maintained until the end of the experiments.

Ischemia

Transient global forebrain ischemia was induced by the 4-VO method (15) with modifications (16). Briefly, the animals were anesthetized with ether plus local application of 2% xylocaine, and were fixed in a stereotaxic-like frame; the vertebral arteries were then bilaterally electrocoagulated. Subsequently, the animals were placed in the supine position and the carotid arteries were carefully isolated from the adjacent tissues and loosely snared with a silk thread.

Five to six hours later the thread was gently tightened for a period of 15 min. Loss of the righting reflex within 2 min of carotid occlusion, unresponsiveness to gentle touch, mydriasis, and tonic extension of the paws were considered to indicate effective ischemia. If loss of the righting reflex did not occur within the first 2 min of carotid occlusion, or if the righting reflex was recovered before the end of ischemia, the animal was excluded from the experiment. Throughout occlusion and during the first hour of reperfusion, the rats were maintained in a warming box at 30°C (17). Core temperature was
monitored but not controlled during the ischemic period, and up to 3.5 h of reperfusion, using a rectal probe inserted to a depth of approximately 6 cm.

Sham-operated animals were submitted to the same manipulations, except for vertebral and carotid occlusion. Experimental procedures followed the ethical principles established by the Brazilian College of Animal Experimentation (www.meusite.com.br/COBEA/index.htm).

Drug treatment

In the first experiment, FK506 was administered iv via the penile vein in single doses (1.0, 3.0, or 6.0 mg/kg, in a volume of 0.1 ml/100 g body weight) immediately after the beginning of reperfusion. In a second experiment, 1.0 mg FK506/kg was given iv at reperfusion (time = 0 h) followed by ip injections applied 6, 24, 48 and 72 h post-ischemia. In the third study, repeated doses of FK506 (1.0 mg/kg) were administered only by the iv route, but at the same intervals as in the second experiment. Control animals received vehicle alone (0.1 ml/100 g) as single or repeated injections where appropriate. Both FK506 (solution, 10 mg/ml ampoule) and vehicle (polyoxymethylene hydrogenated castor oil 60 and anhydrous ethanol) were kindly supplied by the Fujisawa Pharmaceutical Co., Osaka, Japan.

Histological analysis

Seven or thirty days after ischemia, the brain was removed for histological assessment of ischemic lesions in the hippocampus. The animals were deeply anesthetized with ether and perfused transcardiatically with 0.9% saline followed by Bouin’s fixative (20 ml/min for 7-10 min). Following decapitation, the head was immersed in crushed ice (1-2°C) for 1 h. The brain was then carefully removed and kept in Bouin’s fluid for 3 days.

In the first experiment (dose-response curve), ischemic damage was assessed at a level corresponding to approximately 4.52 mm posterior to bregma (18). Eight to twelve paraffin-embedded coronal sections (5-µm thickness) were taken from each brain and stained with celestine blue/acid fuschin. Three sections from each stereotaxic level were chosen for bilateral counts of normal-appearing neurons in the CA1 pyramidal stratum. Thus, six fields/level were counted for each rat, the number of cells in each level being expressed as the mean of the six fields. Fields were chosen by centering the 400X microscopic field laterally and close to the apex of the CA1 sectors in each respective level. The number of intact pyramidal cells with a distinct nucleus and nucleolus was counted along a transect of 450-µm length (approximately 0.160 mm²). In subsequent experiments, the histological analysis was expanded to include two additional stereotaxic coronal planes, which corresponded approximately to 3.60 and 5.30 mm posterior to bregma. The identity of the treatment groups was not revealed during histological assessment.

Statistical analysis

The Kruskal-Wallis test was used to evaluate the effects of FK506 on ischemia-induced hippocampal CA1 neurodegeneration. In the second and third experiments, a separate test was used for data obtained at each stereotaxic level. When a significant main effect appeared, Dunn’s multiple range test was performed to determine differences among the treatment groups. The effect of FK506 on rectal temperature was analyzed by MANOVA for repeated measures. In the case of a significant group effect, the Newman-Keuls multiple range test was used to distinguish the groups.

Results

Figure 1 shows the dose-effect relation-
A dose-response effect of FK506 on ischemia-induced CA1 cell death. Fifteen minutes of 4-VO caused marked CA1 cell loss (92.6%) (P<0.001, sham vs vehicle, Dunn’s multiple comparison test). This neurodegenerative effect of ischemia was not mitigated by a single iv dose of FK506, whatever the concentration used (P=0.05, vehicle vs FK506). In contrast, repeated doses of FK506 were effective in reducing the neurodegenerative effect of ischemia (Figure 2A and B). Fifteen minutes of 4-VO caused pronounced CA1 cell loss at all coronal levels analyzed (77.4-93.2%, P<0.001, sham vs vehicle). When given repeatedly (1 iv injection + 4 ip injections), FK506 reduced the degree of cell death at all levels, independently of whether the animals were sacrificed 7 or 30 days post-ischemia (P<0.01-0.001, vehicle vs FK506, Dunn’s multiple comparison test). In animals analyzed 30 days post-ischemia, neuroprotection was seen at the medial and temporal levels of the hippocampus (Figure 2B: P<0.05, vehicle vs FK506), but not at the most rostral level (P>0.05). The degree of neuroprotection provided by FK506 varied as a function of the septotemporal level; this differential effect was clearly evident in the 7-day post-ischemic group (Figure 2A; F_{1,40} = 12.36, P = 0.0011), but was reduced in the 30-day group (Figure 2B, F_{1,37} = 3.64, P = 0.064). Regression analysis for the vehicle-treated groups also revealed that the severity of ischemia decreased from the septal to the temporal pole of the hippocampus in both the 7-day and 30-day post-ischemic groups (Figure 2A: F_{1,19} = 7.75, P = 0.012; Figure 2B: F_{1,25} = 7.61; P<0.011). In the sham-
operated group, the number of CA1 pyramidal neurons was unaltered among the various stereotaxic planes (linear regression: P > 0.05). Representative photomicrographs of the hippocampus of rats treated with vehicle or FK506 are illustrated in Figure 3.

Figure 4 shows the results of repeated iv administration of FK506 (1.0 mg/kg), given 0, 6, 24, 48 and 72 h post-ischemia. As seen previously, 15 min of ischemia led to pronounced CA1 neurodegeneration at all septotemporal levels (P < 0.01, sham vs vehicle, Dunn’s multiple comparison test), with the severity of ischemia decreasing from the septal to the temporal pole of the hippocampus (F_{1,25} = 13.4, P = 0.0012). Repeated iv injections of FK506 failed to reduce ischemia-induced CA1 cell death (P > 0.05) at all septotemporal levels.

The effect of FK506 on core temperature is illustrated in Figure 5. At all concentrations used, FK506 reduced rectal temperature compared to the vehicle group (P < 0.05-0.001, Newman-Keuls test). However, this effect did not alter the state of normothermia (approximately 37°C), at least over the period during which temperature was monitored.

![Figure 3. Photomicrographs of coronal sections of the hippocampus at stereotaxic levels corresponding to -3.60 mm (I), -4.52 mm (II) and -5.30 mm (III) in rats subjected to sham operation (A), ischemia plus vehicle (B) or ischemia plus FK506 (C), at magnifications of 20X (left) and 400X (right). Hippocampal damage was assessed 7 days after ischemia. White circles (left panels) indicate the approximate location of the cell counts in the CA1 field. Intact-appearing pyramidal neurons are indicated by arrows. Bars = 100 μm (20X) and 20 μm (400X).]
Discussion

The present study demonstrates that FK506 can attenuate hippocampal damage in models of transient global forebrain ischemia. Our data extend previous findings to the rat 4-VO model and suggest that such an effect may depend on a repeated dose protocol.

In the first experiment, a single intravenous injection of FK506 provided no neuroprotection, whatever the concentration used (1.0, 3.0, or 6.0 mg/kg). This result does not confirm a previous finding that a single (3.0 or 10.0 mg/kg) dose injected iv immediately after ischemia resulted in robust neuroprotection of CA1 pyramidal cells (7). This discrepancy may be partially explained by the differences observed in the effect of FK506 on core temperature in each study. In the study by Ide et al. (7), FK506 caused a substantial and dose-dependent reduction in core temperature, i.e., 34° and 32°C, respectively. In the present experiment, FK506 did not induce hypothermia.

Significant and sustained neuroprotection was provided, however, when FK506 was given repeatedly, as a combination of iv (1x) plus ip (4x) injections. Again, although rectal temperature was reduced by up to 1°C compared to vehicle-treated animals, this decrease was far from that at which hypothermia is considered to be neuroprotective, i.e., less than 33°C. Thus, the neuroprotective effect does not appear to be due to the influence of FK506 on core temperature. This finding agrees with other studies. In the gerbil, a single injection of FK506 (1.0 mg/kg) ip did not prevent ischemia-induced CA1 cell death. In contrast, the same dose given daily for four days provided neuroprotection, without hypothermia during the 24 h following FK506 administration (8,9). In rats, FK506 prevented ischemia-induced brain damage without reducing core temperature when given daily for 4 (10) or 14 days (19).

In the present study, rectal temperature was recorded for up to 3.5 h post-ischemia (Figure 5); we cannot rule out the possibility that hypothermia may have occurred subsequent to FK506 given 6, 24, 48 or 72 h post-ischemia.

In the present study, the neuroprotective efficacy of FK506 increased from the septal to the temporal pole of the hippocampus. In contrast, the severity of ischemia declined slightly but significantly along the same axis. This may influence the degree of neuropro-
Neuroprotection by FK506 after transient forebrain ischemia

FK506 following repeated and combined iv plus ip injections (Figure 2), it must be emphasized that some animals showed no benefit from FK506. Such a “bimodal” distribution of ischemic CA1 damage has also been reported after treatment with different compounds, such as the AMPA receptor antagonist, NBQX (27,28), the benzodiazepine agonist, diazepam (24,29,30), and the partial benzodiazepine agonist, imidazenil (24). Such variability in response is thought to result from a combination of at least two factors, i.e., normal variation of damage in the model, and differences in the real concentration of the drug which reaches the brain in each individual (27). We considered this last factor in the present study, and the third experiment (Figure 4) was designed to test whether FK506 efficacy could be increased when all five doses were administered by the iv route alone. The rationale was that by increasing FK506 bioavailability, greater neuroprotective efficacy might be provided. Unexpectedly, however, no neuroprotection was obtained using this schedule. At present, we have no explanation for this finding.

In conclusion, the present study further demonstrates that FK506 reduces the extent of neuronal death in the hippocampus after transient global cerebral ischemia in rats, and extends to the rat 4-VO model previous observations that FK506 protects against ischemia in a sustained manner. This effect may depend on a schedule of repeated doses via different delivery routes. However, more detailed studies are needed to assess the most appropriate treatment protocol that provides the greatest efficacy of FK506. Additional studies are also required to investigate the therapeutic window of the neuroprotective effect of FK506. At present, we are investigating whether the neuroprotective effect of FK506 observed at the histological level is accompanied by attenuation of ischemia-induced, spatial learning and memory dysfunction.
Acknowledgments

The authors gratefully acknowledge the technical assistance of Ricardo A. Paganelli (computer-assisted images) and Marcos A. Trombelli (animal care).

References